Devices for Dry Powder Drug Delivery to the Lung

AAPS PharmSciTech

Volumn 16, Issue 3, 2015, Pages 479-490

  Berkenfeld, Kai ^a,b   Lamprecht, Alf ^b   McConville, Jason T ^a,b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

disposable; dry powder inhaler; particle deagglomeration; vaccination

Indexed keywords

ACLIDINIUM BROMIDE; ANALGESIC AGENT; BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE; FENTANYL; FLUTICASONE FUROATE PLUS VILANTEROL; INDACATEROL; LANINAMIVIR; LOXAPINE; MANNITOL; RECOMBINANT HUMAN INSULIN; SALBUTAMOL; SALBUTAMOL SULFATE; TOBRAMYCIN; UMECLIDINIUM PLUS VILANTEROL; VACCINE; ZANAMIVIR; DRUG; POWDER;

AEROSOL; ARTICLE; DISPOSABLE EQUIPMENT; DRY POWDER; DRY POWDER INHALER; HUMAN; LUNG; METERED DOSE INHALER; NEBULIZER; PRIORITY JOURNAL; ADMINISTRATION AND DOSAGE; DEVICES; DRUG DELIVERY SYSTEM; DRUG EFFECTS; EQUIPMENT DESIGN; INHALATIONAL DRUG ADMINISTRATION; POWDER; REPRODUCIBILITY;

ADMINISTRATION, INHALATION; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; EQUIPMENT DESIGN; HUMANS; LUNG; PHARMACEUTICAL PREPARATIONS; POWDERS; REPRODUCIBILITY OF RESULTS;

EID: 84929957514     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-015-0317-x     Document Type: Article

References (108)

1. Crompton G. A brief history of inhaled asthma therapy over the last fifty years. Prim Care Respir J. 2006;15(6):326–31.
2. Molina MJ, Rowland FS. Stratospheric sink for chlorofluoromethanes: chlorine atom-catalysed destruction of ozone. Nature. 1974;249:810–2.
3. UNEP. The Montreal Protocol on substances that deplete the ozone layer. http://ozone.unep.org/pdfs/Montreal-Protocol2000.pdf. Accessed 22 Feb 2014.
4. Department of Health and Human Services. Use of ozone-depleting substances; removal of essential use designations. Fed Regist. 2005;70(63):17167–92.
5. Department of Health and Human Services. Use of ozone-depleting substances; removal of essential use designations (flunisolide etc.). Fed Regist. 2010;75(71):19213–41.
6. Myrdal PB, Sheth P, Stein SW. Advances in metered dose inhaler technology: formulation development. AAPS PharmSciTech. 2014;15(2):434–55.
7. Sanders M. Inhalation therapy: an historical review. Prim Care Respir J. 2007;16(2):71–81.
8. McDonald KJ, Martin GP. Transition to CFC-free metered dose inhalers—into the new millennium. Int J Pharm. 2000;201(1):89–107.
9. Oenbrink RJ. Unexpected adverse effects of Freon 11 and Freon 12 as medication propellants. J Am Osteopath Assoc. 1993;93(6):714–8.
10. Bryant DH, Pepys J. Bronchial reactions to aerosol inhalant vehicle. Br Med J. 1976;1(6021):1319–20.
11. Smyth HDC. The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. Adv Drug Deliv Rev. 2003;55(7):807–28.
12. Soine WH, Blondino FE, Byron PR. Chemical stability in pressurized inhalers formulated as solutions. J Biopharm Sci. 1992;3(1):41–7.
13. Philips EM, Byron PR. Surfactant promoted crystal growth of micronized methylprednisolone in trichloromonofluoromethane. Int J Pharm. 1994;110(1):9–19.
14. Johnson KA. Interfacial phenomena and phase behavior in metered-dose inhaler formulations. In: Hickey AJ, editor. Inhalation aerosols (94). New York: Marcel Dekker; 1996. pp. 385–415.
15. Son YJ, McConville JT. Advancements in dry powder delivery to the lung. Drug Dev Ind Pharm. 2008;34(9):948–59.
16. O’Connor BJ. The ideal inhaler: design and characteristics to improve outcomes. Respir Med. 2004;98(Suppl A):10–6.
17. Stein SW, Sheth P, Hodson PD, Myrdal PB. Advances in metered dose inhaler technology: hardware development. AAPS PharmSciTech. 2014;15(2):326–38.
18. Clark AR. Medical aerosol inhaler: past, present, and future. Aerosol Sci Technol. 1995;22(4):374–91.
19. Barnes PJ, Stockley RA. COPD: current therapeutic interventions and future approaches. Eur Respir J. 2005;25(6):1084–106.
20. Keating GM. Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. CNS Drugs. 2013;27(6):479–89.
21. Riley A, Main M, Morgan F. Inhalation device allows novel administration of apomorphine in men with erectile dysfunction - efficacy and safety findings. J Sex Med. 2010;7(4 Pt 1):1508–17.
22. Siekmeier R, Scheuch G. Inhaled insulin - does it become reality? J Physiol Pharmacol. 2008;59 suppl 6:81–113.
23. Friebel C, Steckel H. Single-use disposable dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv. 2010;7(12):1359–72.
24. Labiris NR, Dolovich MB. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56(6):588–99.
25. Vanbever R, Mintzes JD, Wang J, et al. Formulation and physical characterization of large porous particles for inhalation. Pharm Res. 1999;16(11):1735–42.
26. Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care. 2005;50(9):1209–27.
27. Dunbar CA, Hickey AJ, Holzner P. Dispersion and characterization of pharmaceutical dry powder aerosols. Kona Powder Part J. 1998;16:7–45.
28. Young PM, Sung A, Traini D, Kwok P, Chiou H, Chan HK. Influence of humidity on the electrostatic charge and aerosol performance of dry powder inhaler carrier based systems. Pharm Res. 2007;24(5):963–70.
29. Chow AHL, Tong HHY, Chattopadhyay P, Shekunov BY. Particle engineering for pulmonary drug delivery. Pharm Res. 2007;24(3):411–37.
30. Voss A, Finlay WH. Deagglomeration of dry powder pharmaceutical aerosols. Int J Pharm. 2002;248(1–2):39–50.
31. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers - implications for in vitro testing. J Aerosol Med. 1993;6(2):99–110.
32. Tiddens, Geller DE, Challoner P. Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older. J Aerosol Med. 2006;19(4):456–65.
33. Feddah MR, Brown KF, Gipps EM, Davies NM. In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates. J Pharm Pharm Sci. 2000;3(3):318–24.
34. Chan JGY, Wong J, Zhou QT, Leung SSY, Chan H-K. Advances in device and formulation technologies for pulmonary drug delivery. AAPS PharmSciTech. 2014;15(4):882–97.
35. Timsina MP, Martin GP, Marriott C, Ganderton D, Yianneskis M. Drug delivery to the respiratory tract using dry powder inhalers. Int J Pharm. 1994;101(1–2):1–13.
36. Bisgaard H. Delivery of inhaled medication to children. J Asthma. 1997;34(6):443–67.
37. Zainudin BM, Biddiscombe M, Tolfree SE, Short M, Spiro SG. Comparison of bronchodilator responses and deposition patterns of powder, and as a nebulised solution. Thorax. 1990;45(6):469–73.
38. Richards R, Dickson CR, Renwick AG, Lewis RA, Holgate ST. Absorption and disposition kinetics of cromolyn sodium and the influence of inhalation technique. J Pharmacol Exp Ther. 1987;241(3):1028–32.
39. Chodosh S, Flanders JS, Kesten S, Serby CW, Hochrainer D, Witek Jr TJ. Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J Aerosol Med. 2001;14(3):309–15.
40. Newman SP, Sutton DJ, Segarra R, Lamarca R, de Miquel G. Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler. Respiration. 2009;78(3):322–8.
41. Islam N, Cleary MJ. Developing an efficient and reliable dry powder inhaler for pulmonary drug delivery - a review for multidisciplinary researchers. Med Eng Phys. 2012;34(4):409–27.
42. Claus S, Weiler C, Schiewe J, Friess W. How can we bring high drug doses to the lung? Eur J Pharm Biopharm. 2014;86(1):1–6.
43. Smith IJ, Parry-Billings M. The inhalers of the future? A review of dry powder devices on the market today. Pulm Pharmcol Ther. 2003;16(2):79–95.
44. Islam N, Gladki E. Dry powder inhalers (DPIs) - a review of device reliability and innovation. Int J Pharm. 2008;360(1–2):1–11.
45. Yadav N, Lohani A. Dry powder inhalers: a review. IGJPS. 2013;3(2):142–53.
46. Blau H, Mussaffi H, Mei Zahav M, Prais D, Livne M, Czitron BM, et al. Microbial contamination of nebulizers in the home treatment of cystic fibrosis. Child Care Health Dev. 2007;33(4):491–5.
47. VanDevanter DR, Geller DE. Tobramycin administered by the TOBI® podhaler for persons with cystic fibrosis: a review. Med Devices. 2011;4:179–88.
48. Konstan MW, Flume PA, Kappler M et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros. 2011;10(1):54–61.
49. Harsch IA, Hahn EG, Konturek PC. Syringe, pen, inhaler - the evolution of insulin therapy. Med Sci Monit. 2001;7(4):833–36.
50. Kling J. Dreamboat sinks prospects for fast approval of inhaled insulin. Nat Biotechnol. 2011;29(3):175–6.
51. drugs@FDA database. Food and drug administration. http://www.accessdata.fda.gov. Accessed 20 Dec 2014
52. drugs@FDA database. Food and drug administration. http://www.accessdata.fda.gov. Accessed 11 Dec 2013.
53. Chrystyn H, Niederlaender C. The Genuair inhaler: a novel, multidose dry powder inhaler. Int J Clin Pract. 2012;66(3):309–17.
54. Magnussen H, Watz H, Zimmermann I, Macht S, Greguletz R, Falques M, et al. Peak inspiratory flow through the Genuaira inhaler in patients with moderate or severe COPD. Respir Med. 2009;103(12):1832–7.
55. Buhl R, Banerij D. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:729–41.
56. Arcapta medication guide. Novartis, Basel, Switzerland. http://www.fda.gov. Accessed 6 Jan 2014.
57. Pavkov R, Mueller S, Fiebich K, et al. Characteristics of a new capsule based dry powder inhaler for the effective delivery of indacaterol. Curr Med Res Opin. 2010;26(11):2527–33.
58. Chapman KR, Fogarty CM, Peckitt C, et al. Delivery characteristics and patients’ handling of two single-dose dry powder inhalers used in COPD. Int J Chron Obstruct Pulmon Dis. 2011;6:353–63.
59. Clinicaltrials.gov database, ID: NCT01915784. NIH. http://www.clinicaltrials.gov. Accessed 20 Feb 2014
60. Geller DE, Weers J, Heuerding S. Development of an inhaled dry powder formulation of tobramycin using PulmoSphere technology. J Aerosol Med Pulm Drug Deliv. 2011;24(4):175–82.
61. Newhouse MT, Hirst PH, Duddu SP, Walter YH, Tarara TE, Clark AR, et al. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest. 2003;124(1):360–6.
62. Maltz DS, Paboojian SJ. Device engineering insights into TOBI Podhaler: a development case study of high efficient powder delivery to cystic fibrosis patients. In: Dalby RN, Byron PR, Peart J, Suman JD, Young PM, editors. Proceedings of RDD Europe 2011. River Grove: Davis Healthcare International Publication; 2011. pp. 55–65.
63. Haynes A, Nakamura J, Heng C, Heuerding S, Thompson G, Malcolmson R. Aerosol performance of tobramycin inhalation powder. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM, editors. Proceedings of RDD 2010. River Grove: Davis Healthcare International Publication; 2010. pp. 701–6.
64. Brambilla G, Coconi D, Armanni A, Smith S, Lye E, Burge S. Designing a novel dry powder inhaler: the NEXT DPI (part 1). In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM, editors. Proceedings of RDD 2006. River Grove: Davis Healthcare International Publication; 2006; pp. 553–6.
65. Chiesi Farmaceutici, Parma, Italy. Fachinfo Foster (medication guide, GER). http://www.fachinfo.de/. Accessed 9 Jan 2014.
66. Pasquali I, Brambilla G, Copelli D. Effect of flow rate on dose delivery of three dry powder inhalers: NEXThaler, Turbohaler and Diskus. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM, editors. Proceedings of RDD 2013. River Grove: Davis Healthcare International Publication; 2013. pp. 267–72.
67. Leone-Bay A, Baughman R, Smutney C, Kocinsky J. Innovation in drug delivery by inhalation. On Drug Deliv. 2010;4(7):4–8.
68. ε-(fumaroyl)diketopiperazine of L-Lys (FDKP) interactions. Mol Pharm. 2008;5(2):294–315.
69. Pfützner A, Forst T. Pulmonary insulin delivery by means of Technosphere drug carrier mechanism. Expert Opin Drug Deliv. 2005;2(6):1097–106.
70. Soares S, Costa A, Sarmento B. Novel non-invasive methods of insulin delivery. Expert Opin Drug Deliv. 2012;9(12):1539–58.
71. Angelo R, Rousseau K, Grant M, Leone-Bay A, Richardson P. Technosphere® insulin: defining the role of Technosphere particles at cellular level. J Diabetes Sci Technol. 2009;3(3):545–54.
72. Marino MT, Cassidy JP. The relationship between two insulin assays used to determine bioequivalence and dose proportionality of Afrezza insulin administered using a gen2 inhaler compared to a MedTone inhaler: simulation of clinical trials and actual data. Poster presented at: Diabetes Technology Meeting 2010 Nov 11–13. Bethesda, MD, USA.
73. Leone-Bay A, Smutney C, Kocinsky J. Pulmonary drug delivery—simplified. OnDrugDeliv. 2011;5(5):18–21.
74. Gagnadoux F, Hureaux J, Vecellio L, et al. Aerosolized chemotherapy. J Aerosol Med Pulm Drug Deliv. 2008;21(1):61–70.
75. Sullivan VJ, Mikszta JA, Laurent P, Huang J, Ford B. Noninvasive delivery technologies: respiratory delivery of vaccines. Expert Opin Drug Deliv. 2006;3(1):87–95.
76. Worsley MH, Macleod AD, Brodie MJ, Asbury AJ, Clark C. Inhaled fentanyl as a method of analgesia. Anaesthesia. 1990;45(6):449–51.
77. drugs@FDA database. Food and drug administration. http://www.accessdata.fda.gov. Accessed 20 Dec 2014.
78. Sou T, Meeusen EN, de Veer M, Morton DAV, Kaminskas LM, McIntosh MP. New developments in dry powder pulmonary vaccine delivery. Trends Biotechnol. 2011;29(4):191–8.
79. EDQM. European pharmacopoeia. 8th ed. Strasbourg: Council of Europe Publishing; 2013.
80. Brandau DT, Jones LS, Wiethoff CM, Rexroad J, Middaugh CR. Thermal stability of vaccines. J Pharm Sci. 2003;92(2):218–31.
81. Carstens MG. Opportunities and challenges in vaccine delivery. Euro J Pharm Sci. 2009;36(4-5):605–8.
82. WHO. Progress towards global immunization goal—2012 http://www.who.int. Accessed 4 Jan 2014
83. Clayborough R, Simpson I. DPI technologies: time for a rethink. IPT. 2010;14:74–9.
84. Grosset KA, Malek N, Morgan F, Grosset DG. Inhaled dry powder apomorphine (VR040) for ‘off ’ periods in Parkinson’s disease: an in-clinic double-blind dose ranging study. Acta Neurol Scand. 2013;128(3):166–71.
85. De Boer AH, Hagedoorn P, Westerman EM, Le Brun PPH, Heijerman HGM, Frijlink H. Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer) for high powder doses. Euro J Pharm Sci. 2006;28:171(3)–8.
86. Westermann EM, De Boer AH, Le Brun PPH, Touw DJ, Roldaan AC, Frijlink HW, et al. Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study. J Cyst Fibros. 2007;6(4):284–92.
87. Lexmond AJ, Hagedoorn P, van der Wiel E, Ten Hacken NH, Frijlink HW, de Boer AH. Adenosine dry powder inhalation for bronchial challenge testing, part 1: inhaler and formulation development and in vitro performance testing. Eur J Pharm Biopharm. 2014;86(1):105–14.
88. Saluja V, Amorij JP, Kapteyn JC, de Boer AH, Frijlink HW, Hinrichs WLJ. A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation. J Control Release. 2010;144(2):127–33.
89. Needham M, Fradley G, Cocks P. Investigating the efficiency of reverse cyclone technology for DPI drug delivery. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM, editors. Proceedings of RDD 2010 (2). River Grove: Davis Healthcare International Publication; 2010. pp. 369–72.
90. Harris DS, Smith SJ, inventors; Cambridge Consultants Ltd., assignee. Dry powder inhalers. US Patent 8261739. 11 Sept 2012.
91. Villax P, McDerment IG, Bunce M, inventors; Hovione International Ltd., assignee. A simple inhaler. US patent 8109267. 7 Feb 2012.
92. Tibbats J, Mendes PJ, Villax P. Understanding the power requirements for efficient dispersion in powder inhalers: comparing CFD predictions and experimental measures. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM, editors. Proceedings of RDD 2010 (1). River Grove: Davis Healthcare International Publication; 2010. p. 323–30.
93. Dinh K, Myers DJ, Glazer M, Shmidt T, Devereaux C, Simis K, et al. In vitro aerosol characterization of Staccato Loxapine. Int J Pharm. 2011;403(1–2):101–8.
94. Teva select brands, Horsham, US. Adasuve prescribing information. http://www.adasuve.com. Accessed 6 Jan 2014
95. Noymer P, Myers DJ, Glazer M, Fishman R, Casella J. The Staccato system: inhaler design characteristics for rapid treatment of CNS disorders. In: Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM, editors. Proceedings of RDD 2010 (1). River Grove: Davis Healthcare International Publication; 2010. p. 13–21.
96. Myers DJ, Timmons RD, Lu AT, Hale RL, Solas DW, Soni P, et al. Effect of film thickness on thermal aerosol generation. Pharm Res. 2006;24(2):336–42.
97. Noymer PD, Myers DJ, Casella JV, Timmons R. Assessing the temperature of thermally generated inhalation aerosols. J Aerosol Med Pulm Drug Deliv. 2011;24(1):11–5.
98. Dinh KV, Myers DJ, Noymer PD, Casella JV. In vitro aerosol deposition in the oropharyngeal region for Staccato® Loxapine. J Aerosol Med Pulm Drug Deliv. 2010;23(4):253–60.
99. Myers DJ, Spyker DA, Dinh K, Quintana RJ, Cassella JV. Consistency of dosing with a thermal aerosol generation system: in vitro and in vivo correlation. Future Med Chem. 2011;3(13):1719–33.
100. Rabinowitz JD, Lloyd PM, Munzar P et al. Ultra-fast absorption of amorphous pure drug aerosols via deep lung inhalation. J Pharm Sci. 2006;95(11):2438–50.
101. Simis K, Lei M, Lu AT, Sharma KCV, Hale RL. Nicotine aerosol generation from thermally reversible zinc halide complexes using the Staccato system. Drug Dev Ind Pharm. 2008;34(9):936–42.
102. Macleod DB, Habib AS, Ikeda K, Spyker DA, Cassella JV, Ho KY, et al. Inhaled fentanyl aerosol in healthy volunteers: pharmacokinetics and pharmacodynamics. Anesth Analg. 2012;115(5):1071–7.
103. Alexza Pharmaceuticals. Staccato product pipeline. http://alexza.com Accessed 6 Jan 2014.
104. Adler D, Kritzman A, Holtz A, inventors; Aespira Ltd., assignee. Dry powder inhaler. United States patent 13/575908. 21 Feb 2013.
105. Clinicaltrials.gov database, ID:NCT01252758. NIH. http://www.clinicaltrials.gov. Accessed 6 Jan 2014.
106. Smutney CC et al., inventors; MannKind Corp., assignee. Dry powder inhaler and system for drug delivery. United States patent 8636001. 28 Jan 2014.
107. Team Consulting (Cambridge, UK). Occoris white paper. http://www.team-consulting.com. Accessed 6 Jan 2014.
108. Jones A, Miller RL, inventors; Manta Corp., assignee. Dose delivery device for inhalation. United States patent 8291901. 23 Oct 2012.